Case Report: Durable response to tislelizumab monotherapy in microsatellite-stable, BRAF V600E-mutant right-sided colon cancer with extremely high PD-L1 expression
Abstract
Colorectal cancer with proficient mismatch repair (pMMR)/microsatellite stable (MSS) status is generally intrinsically resistant to immune checkpoint inhibitors; tumors with concomitant BRAF V600E mutations are highly aggressive, and conventional chemotherapy and targeted therapies have limited efficacy, resulting in a lack of effective personalized treatment options in clinical practice. This report describes a case of locally advanced right-sided colon adenocarcinoma that was pMMR/MSS, harbored a BRAF V600E mutation, and exhibited high programmed death-ligand 1 (PD-L1) expression (tumor proportion score [TPS] > 95%). The patient developed intestinal obstruction after failure of first-line conversion therapy. After undergoing palliative gastrojejunostomy and cecostomy, she developed gastroparesis and a liver abscess. Given the extremely high PD-L1 expression, tislelizumab monotherapy was initiated before the patient’s general condition had fully recovered. After three cycles, the patient’s performance status improved significantly. She then received a combination of tislelizumab and raltitrexed for two cycles; however, chemotherapy was discontinued due to raltitrexed-induced liver injury, and the patient continued maintenance therapy with tislelizumab monotherapy, achieving a partial response (PR) as the best outcome. After nine cycles of maintenance therapy, a new mass appeared in the right adnexal region, indicating disease progression; the overall progression-free survival (PFS) was 14 months. To the best of our knowledge, this is the first reported case of a patient with colorectal adenocarcinoma harboring a BRAF V600E mutation, characterized by extremely high PD-L1 expression and pMMR/MSS status, who achieved a PR with a regimen centered on programmed cell death protein 1 (PD-1) inhibitor monotherapy. This case suggests that for BRAF V600E-mutated colorectal cancer, assessment of PD-L1 expression levels should be considered regardless of mismatch repair status; if extremely high PD-L1 expression is present, even in the pMMR/MSS phenotype, PD-1 inhibitors may offer a potential personalized treatment option for these patients with poor prognosis and limited therapeutic choices.
Related
- [Comment] Node-sparing modified short-course radiotherapy combined with CAPOX and tislelizumab versus conventional short-course preoperative chemoradiotherapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (mRCAT- Ⅲ): a multicenter, randomized, openlabel, phase 3 trial
- Potential utility of more subtle microsatellite instability for predicting response to nivolumab in gastric cancer patients
- Pathological Complete Response and Successful Conversion Hepatectomy in Initially Unresectable Giant Hepatocellular Carcinoma Following Triple Therapy With HAIC, Bevacizumab, and Tislelizumab: A Case Report
- Exceptionally Durable Response to First-Line S-1 Monotherapy in Metastatic Pancreatic Adenocarcinoma: A Case Report
- Durable complete response to tislelizumab in advanced pMMR cervical cancer and successful rechallenge after immune-related NSTEMI: a case report.
BibTeX
@article{li2026case,
title = {{Case Report: Durable response to tislelizumab monotherapy in microsatellite-stable, BRAF V600E-mutant right-sided colon cancer with extremely high PD-L1 expression}},
author = {Chen Li and Mingyan Li and Simin Wang and Mingxin Xu and Haiyan Liu},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.2004627},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.2004627},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Case Report: Durable response to tislelizumab monotherapy in microsatellite-stable, BRAF V600E-mutant right-sided colon cancer with extremely high PD-L1 expression
AU - Chen Li
AU - Mingyan Li
AU - Simin Wang
AU - Mingxin Xu
AU - Haiyan Liu
PY - 2026
DA - 2026/11/06
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.2004627
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.2004627
AB - Colorectal cancer with proficient mismatch repair (pMMR)/microsatellite stable (MSS) status is generally intrinsically resistant to immune checkpoint inhibitors; tumors with concomitant BRAF V600E mutations are highly aggressive, and conventional chemotherapy and targeted therapies have limited efficacy, resulting in a lack of effective personalized treatment options in clinical practice. This report describes a case of locally advanced right-sided colon adenocarcinoma that was pMMR/MSS, harbored a BRAF V600E mutation, and exhibited high programmed death-ligand 1 (PD-L1) expression (tumor proportion score [TPS] > 95%). The patient developed intestinal obstruction after failure of first-line conversion therapy. After undergoing palliative gastrojejunostomy and cecostomy, she developed gastroparesis and a liver abscess. Given the extremely high PD-L1 expression, tislelizumab monotherapy was initiated before the patient’s general condition had fully recovered. After three cycles, the patient’s performance status improved significantly. She then received a combination of tislelizumab and raltitrexed for two cycles; however, chemotherapy was discontinued due to raltitrexed-induced liver injury, and the patient continued maintenance therapy with tislelizumab monotherapy, achieving a partial response (PR) as the best outcome. After nine cycles of maintenance therapy, a new mass appeared in the right adnexal region, indicating disease progression; the overall progression-free survival (PFS) was 14 months. To the best of our knowledge, this is the first reported case of a patient with colorectal adenocarcinoma harboring a BRAF V600E mutation, characterized by extremely high PD-L1 expression and pMMR/MSS status, who achieved a PR with a regimen centered on programmed cell death protein 1 (PD-1) inhibitor monotherapy. This case suggests that for BRAF V600E-mutated colorectal cancer, assessment of PD-L1 expression levels should be considered regardless of mismatch repair status; if extremely high PD-L1 expression is present, even in the pMMR/MSS phenotype, PD-1 inhibitors may offer a potential personalized treatment option for these patients with poor prognosis and limited therapeutic choices.
SN - 2234-943X
ER -